- MediPharm Labs (TSX:LABS) has commenced production for its novel cannabis metered dose inhalers (MDIs) tailored for the European Union and United Kingdom markets
- These inhalers are manufactured to global pharmaceutical standards and will be distributed exclusively by MediPharm’s dedicated U.K. sales and distribution partner
- MediPharm has already introduced the product in Canada’s adult use and wellness and medical channels and anticipates launches in Australia, the E.U., and the U.K. in Q3 2025
- MediPharm Labs stock (TSX:LABS) last traded at $0.07
MediPharm Labs (TSX:LABS) has announced the commencement of production for its novel cannabis metered dose inhalers (MDIs) tailored for the European Union and United Kingdom markets.
In a media release, the pharmaceutical company specializing in precision-based cannabinoids explained that these inhalers are manufactured to global pharmaceutical standards and will be distributed exclusively by Blackpoint Ltd., MediPharm’s dedicated sales and distribution partner in the region.
The discreet, smoke-free inhalers can offer patients a fast-acting alternative to traditional cannabis consumption methods, delivering precise doses of cannabis active pharmaceutical ingredients (APIs) without combustion or heating. Produced under strict Good Manufacturing Practices (GMP), the MDIs incorporate GMP-qualified components and excipients, working to ensure pharmaceutical-grade quality and consistency.
MediPharm has already introduced the product in Canada’s adult use and wellness and medical channels and anticipates launches in Australia, the E.U., and the U.K. in Q3 2025.
As part of the exclusive agreement, MediPharm Labs will serve as the sole supplier and manufacturer of the cannabis MDIs for Blackpoint. The partnership includes minimum purchase obligations, ensuring a consistent supply across the designated markets. MediPharm aims to leverage its established relationships and distribution networks to expand its footprint in the rapidly growing European medicinal cannabis sector, which Prohibition Partners estimates will reach a market value of €834 million in 2024.
This announcement follows a significant milestone for the company, as MediPharm recently advanced toward the $4.5 million cash sale of its Hope facility. However, the company also faces internal challenges. Shareholders have been alerted to allegations made against a dissident shareholder in multiple litigation filings. Apollo Capital has issued a warning to shareholders, citing concerns over continued value destruction and potential insolvency risks following what it described as “disastrous” Q1 financial results. Despite these concerns, MediPharm reported an 11 per cent revenue increase in revenue for the quarter.
MediPharm develops and manufactures pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients and advanced derivative products.
MediPharm Labs stock (TSX:LABS) last traded at $0.07. Though up 25.00 per cent since the year began, the stock has lost 6.25 per cent since this time last year.
Join the discussion: Find out what everybody’s saying about this medical cannabis stock’s Brazilian expansion on the MediPharm Labs Corp. Bullboard and check out Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
